(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.
Imunon's earnings in 2025 is -$15,745,754.On average, 3 Wall Street analysts forecast IMNN's earnings for 2025 to be -$17,348,747, with the lowest IMNN earnings forecast at -$21,150,506, and the highest IMNN earnings forecast at -$13,833,747. On average, 3 Wall Street analysts forecast IMNN's earnings for 2026 to be -$18,777,503, with the lowest IMNN earnings forecast at -$40,014,169, and the highest IMNN earnings forecast at -$6,028,971.
In 2027, IMNN is forecast to generate -$7,060,911 in earnings, with the lowest earnings forecast at -$8,860,395 and the highest earnings forecast at -$5,261,647.